5 Micro-Cap Stocks to Buy According to Hedge Funds

4. Atreca, Inc. (NASDAQ:BCEL)

Number of Hedge Fund Holders: 20

Market Capitalization: $192.8 million

Atreca, Inc. (NASDAQ:BCEL) is involved in developing novel immunotherapies for the treatment of cancer and COVID-19. The San Carlos, California-based company brings into play its proprietary Atreca Discovery Platform to develop these immunotherapies and also partners with leading pharmaceutical organizations like Pfizer Inc. (NYSE:PFE), GlaxoSmithKline plc (NYSE:GSK), and others.

Atreca, Inc. (NASDAQ:BCEL) revealed initial results of Phase 1b research using ATRC-101 in patients with advanced solid tumors. ATRC-101 is a monoclonal antibody. In order to gauge its efficacy, it will be used with pembrolizumab and afterward along with chemotherapy also. The expected data of the combination study with pembrolizumab can be expected next 2022, which if favorable can act as a catalyst in rising stock price.

In addition to this, Atreca, Inc. (NASDAQ:BCEL) recently entered into an agreement with Bill and Melinda Gates Foundation to develop a novel monoclonal antibody to prevent malaria. Atreca, Inc. (NASDAQ:BCEL) anticipates entering a candidate in the approval pipeline by early 2023. The antibody has shown positive results in the prevention of malaria in animals. Under the term of the partnership, the foundation will hold commercial rights for countries under the GAVI program. Meanwhile, Atreca Inc. (NASDAQ:BCEL) would have commercial rights for the US, Europe, and certain countries in Asia.

In October, Tony Butler at Roth Capital issued a Buy rating on Atreca, Inc. (NASDAQ:BCEL) shares with a price target of $30. This reflects a potential upside of nearly five times from the current stock price.